Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists modeled tumor-specific MEK inhibition (MEKi) through CRISPR/Cas-mediated genome editing of tumor cells and pharmacologic MEKi with cobimetinib in a RAS-driven model of colorectal cancer.
[Cancer Immunology Research]
6445218 AG4ZDHX4 items 1 apa 0 default asc 1 165744 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-8a9a2fdb98ff499b6c8f0e4eb2914415%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22AG4ZDHX4%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dennison%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDennison%2C%20L.%2C%20Ruggieri%2C%20A.%2C%20Mohan%2C%20A.%2C%20Leatherman%2C%20J.%2C%20Cruz%2C%20K.%2C%20Woolman%2C%20S.%2C%20Azad%2C%20N.%2C%20Lesinski%2C%20G.%20B.%2C%20Jaffee%2C%20E.%20M.%2C%20%26amp%3B%20Yarchoan%2C%20M.%20%282021%29.%20Context-Dependent%20Immunomodulatory%20Effects%20of%20MEK%20Inhibition%20are%20Enhanced%20with%20T-cell%20Agonist%20Therapy.%20%3Ci%3ECancer%20Immunology%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-21-0147%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-21-0147%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DAG4ZDHX4%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Context-Dependent%20Immunomodulatory%20Effects%20of%20MEK%20Inhibition%20are%20Enhanced%20with%20T-cell%20Agonist%20Therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Dennison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Ruggieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aditya%22%2C%22lastName%22%3A%22Mohan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Leatherman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kayla%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Skylar%22%2C%22lastName%22%3A%22Woolman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilofer%22%2C%22lastName%22%3A%22Azad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20B.%22%2C%22lastName%22%3A%22Lesinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20M.%22%2C%22lastName%22%3A%22Jaffee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Yarchoan%22%7D%5D%2C%22abstractNote%22%3A%22MEK%20inhibition%20%28MEKi%29%20is%20proposed%20to%20enhance%20antitumor%20immunity%20but%20has%20demonstrated%20mixed%20results%20as%20an%20immunomodulatory%20strategy%20in%20human%20clinical%20trials.%20MEKi%20exerts%20direct%20immunomodulatory%20effects%20on%20tumor%20cells%20and%20tumor-infiltrating%20lymphocytes%2C%20but%20these%20effects%20have%20not%20been%20independently%20investigated.%20Here%20we%20modeled%20tumor-specific%20MEKi%20through%20CRISPR%5C%2FCas-mediated%20genome%20editing%20of%20tumor%20cells%20%28MEK1%20KO%29%20and%20pharmacologic%20MEKi%20with%20cobimetinib%20in%20a%20RAS-driven%20model%20of%20colorectal%20cancer.%20This%20approach%20allowed%20us%20to%20distinguish%20tumor-mediated%20and%20tumor-independent%20mechanisms%20of%20MEKi%20immunomodulation.%20MEK1%20KO%20tumors%20demonstrated%20upregulation%20of%20JAK%5C%2FSTAT%20signaling%3B%20enhanced%20MHCI%20expression%2C%20CD8%2B%20T-cell%20infiltration%20and%20T-cell%20activation%3B%20and%20impaired%20tumor%20growth%20that%20is%20immune-dependent.%20Pharmacologic%20MEKi%20recapitulated%20tumor-intrinsic%20effects%20but%20simultaneously%20impaired%20T-cell%20activation%20in%20the%20tumor%20microenvironment.%20We%20confirmed%20a%20reduction%20in%20human%20peripheral%20lymphocyte%20activation%20from%20a%20clinical%20trial%20of%20anti-PD-L1%20%28atezolizumab%29%20with%20or%20without%20cobimetinib%20in%20biliary%20tract%20cancers.%20Impaired%20activation%20of%20tumor-infiltrating%20lymphocytes%20treated%20with%20pharmacologic%20MEKi%20was%20reversible%20and%20was%20rescued%20with%20the%20addition%20of%20a%2041BB%20agonist.%20Collectively%2C%20these%20data%20underscore%20the%20ability%20of%20MEKi%20to%20induce%20context-dependent%20immunomodulatory%20effects%20and%20suggest%20that%20T%20cell-agonist%20therapy%20maximizes%20the%20beneficial%20effects%20of%20MEKi%20on%20the%20antitumor%20immune%20response.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-21-0147%22%2C%22ISSN%22%3A%222326-6066%2C%202326-6074%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fcancerimmunolres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F08%5C%2F13%5C%2F2326-6066.CIR-21-0147%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-08-17T00%3A20%3A05Z%22%7D%7D%5D%7D
Dennison, L., Ruggieri, A., Mohan, A., Leatherman, J., Cruz, K., Woolman, S., Azad, N., Lesinski, G. B., Jaffee, E. M., & Yarchoan, M. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.CIR-21-0147 Cite
